Cargando…
Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients
BACKGROUND: Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. However, metformin’s effects in patients with diabetic VC have not previously been...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311847/ https://www.ncbi.nlm.nih.gov/pubmed/28202017 http://dx.doi.org/10.1186/s12933-017-0509-7 |
_version_ | 1782508103243137024 |
---|---|
author | Mary, Aurélien Hartemann, Agnes Liabeuf, Sophie Aubert, Carole Elodie Kemel, Salim Salem, Joe Elie Cluzel, Philippe Lenglet, Aurélie Massy, Ziad A. Lalau, Jean-Daniel Mentaverri, Romuald Bourron, Olivier Kamel, Saïd |
author_facet | Mary, Aurélien Hartemann, Agnes Liabeuf, Sophie Aubert, Carole Elodie Kemel, Salim Salem, Joe Elie Cluzel, Philippe Lenglet, Aurélie Massy, Ziad A. Lalau, Jean-Daniel Mentaverri, Romuald Bourron, Olivier Kamel, Saïd |
author_sort | Mary, Aurélien |
collection | PubMed |
description | BACKGROUND: Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. However, metformin’s effects in patients with diabetic VC have not previously been characterized. The present study investigated the association between metformin use and lower-limb arterial calcification in patients with type 2 diabetes and high cardiovascular risk. METHODS: The DIACART cross-sectional cohort study included 198 patients with type 2 diabetes but without severe chronic kidney disease. Below-the-knee calcification scores were assessed by computed tomography and supplemented by colour duplex ultrasonography. Data on anti-diabetic drugs were carefully collected from the patients’ medical records and during patient interviews. Biochemical and clinical data were studied as potential confounding factors. RESULTS: Metformin-treated patients had a significantly lower calcification score than metformin-free patients (mean ± standard deviation: 2033 ± 4514 and 4684 ± 9291, respectively; p = 0.01). A univariate analysis showed that metformin was associated with a significantly lower prevalence of severe below-the-knee arterial calcification (p = 0.02). VC was not significantly associated with the use of other antidiabetic drugs, including sulfonylureas, insulin, gliptin, and glucagon like peptide-1 analogues. A multivariate logistic regression analysis indicated that the association between metformin use and calcification score (odds ratio [95% confidence interval] = 0.33 [0.11–0.98]; p = 0.045) was independent of age, gender, tobacco use, renal function, previous cardiovascular disease, diabetes duration, neuropathy, retinopathy, HbA(1c) levels, and inflammation. CONCLUSIONS: In patients with type 2 diabetes, metformin use was independently associated with a lower below-the-knee arterial calcification score. This association may contribute to metformin’s well-known vascular protective effect. Further prospective investigations of metformin’s potential ability to inhibit VC in patients with and without type 2 diabetes are now needed to confirm these results. |
format | Online Article Text |
id | pubmed-5311847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53118472017-02-22 Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients Mary, Aurélien Hartemann, Agnes Liabeuf, Sophie Aubert, Carole Elodie Kemel, Salim Salem, Joe Elie Cluzel, Philippe Lenglet, Aurélie Massy, Ziad A. Lalau, Jean-Daniel Mentaverri, Romuald Bourron, Olivier Kamel, Saïd Cardiovasc Diabetol Original Article BACKGROUND: Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. However, metformin’s effects in patients with diabetic VC have not previously been characterized. The present study investigated the association between metformin use and lower-limb arterial calcification in patients with type 2 diabetes and high cardiovascular risk. METHODS: The DIACART cross-sectional cohort study included 198 patients with type 2 diabetes but without severe chronic kidney disease. Below-the-knee calcification scores were assessed by computed tomography and supplemented by colour duplex ultrasonography. Data on anti-diabetic drugs were carefully collected from the patients’ medical records and during patient interviews. Biochemical and clinical data were studied as potential confounding factors. RESULTS: Metformin-treated patients had a significantly lower calcification score than metformin-free patients (mean ± standard deviation: 2033 ± 4514 and 4684 ± 9291, respectively; p = 0.01). A univariate analysis showed that metformin was associated with a significantly lower prevalence of severe below-the-knee arterial calcification (p = 0.02). VC was not significantly associated with the use of other antidiabetic drugs, including sulfonylureas, insulin, gliptin, and glucagon like peptide-1 analogues. A multivariate logistic regression analysis indicated that the association between metformin use and calcification score (odds ratio [95% confidence interval] = 0.33 [0.11–0.98]; p = 0.045) was independent of age, gender, tobacco use, renal function, previous cardiovascular disease, diabetes duration, neuropathy, retinopathy, HbA(1c) levels, and inflammation. CONCLUSIONS: In patients with type 2 diabetes, metformin use was independently associated with a lower below-the-knee arterial calcification score. This association may contribute to metformin’s well-known vascular protective effect. Further prospective investigations of metformin’s potential ability to inhibit VC in patients with and without type 2 diabetes are now needed to confirm these results. BioMed Central 2017-02-15 /pmc/articles/PMC5311847/ /pubmed/28202017 http://dx.doi.org/10.1186/s12933-017-0509-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Article Mary, Aurélien Hartemann, Agnes Liabeuf, Sophie Aubert, Carole Elodie Kemel, Salim Salem, Joe Elie Cluzel, Philippe Lenglet, Aurélie Massy, Ziad A. Lalau, Jean-Daniel Mentaverri, Romuald Bourron, Olivier Kamel, Saïd Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients |
title | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients |
title_full | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients |
title_fullStr | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients |
title_full_unstemmed | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients |
title_short | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients |
title_sort | association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311847/ https://www.ncbi.nlm.nih.gov/pubmed/28202017 http://dx.doi.org/10.1186/s12933-017-0509-7 |
work_keys_str_mv | AT maryaurelien associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT hartemannagnes associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT liabeufsophie associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT aubertcaroleelodie associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT kemelsalim associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT salemjoeelie associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT cluzelphilippe associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT lengletaurelie associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT massyziada associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT lalaujeandaniel associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT mentaverriromuald associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT bourronolivier associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients AT kamelsaid associationbetweenmetforminuseandbelowthekneearterialcalcificationscoreintype2diabeticpatients |